Seres Therapeutics, Inc.
MCRBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Buy | Mar 13, 2026 |
| Canaccord Genuity | maintain | Buy | Sep 24, 2025 |
| Chardan Capital | downgrade | Buy →Neutral | May 8, 2025 |
| Chardan Capital | maintain | Buy | Mar 20, 2025 |
| Goldman Sachs | maintain | Sell | Mar 14, 2025 |
| Canaccord Genuity | maintain | Buy | Nov 14, 2024 |
| Chardan Capital | maintain | Buy | Nov 13, 2024 |
| JP Morgan | downgrade | Neutral →Underweight | Oct 24, 2024 |
| Canaccord Genuity | maintain | Buy | Sep 13, 2024 |
| Canaccord Genuity | maintain | Buy | Aug 14, 2024 |
| Chardan Capital | maintain | Buy | Aug 14, 2024 |
| Canaccord Genuity | maintain | Buy | Jun 7, 2024 |
| Oppenheimer | downgrade | Outperform →Perform | Jun 7, 2024 |
| Oppenheimer | maintain | Outperform | May 9, 2024 |
| Chardan Capital | maintain | Buy | May 8, 2024 |
| Chardan Capital | maintain | Buy | Mar 6, 2024 |
| Oppenheimer | maintain | Outperform | Mar 6, 2024 |
| Oppenheimer | maintain | Outperform | Jan 16, 2024 |
| Goldman Sachs | maintain | Sell | Nov 3, 2023 |
| Chardan Capital | maintain | Buy | Apr 28, 2023 |
| JP Morgan | maintain | Neutral | Apr 21, 2023 |
| Canaccord Genuity | maintain | Buy | Mar 21, 2023 |
| Chardan Capital | maintain | Buy | Mar 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 8, 2023 |
| Canaccord Genuity | maintain | Buy | Mar 8, 2023 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-1.11| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-1.63 | $-1.00 | $593.0K | $6.3M |
| Aug 5, 2026 | $0.47 | $-2.18 | $736.0K | $179.0K |
| May 5, 2026 | $-2.08 | $-1.88 | $358.0K | $358.0K |
| Mar 12, 2026 | $-1.78 | $-2.39 | $438.0K | $5.3M |
| Nov 5, 2025 | $0.94 | $0.05 | $351.0K | $7.8M |
| Aug 6, 2025 | $-2.27 | $-2.72 | — | $5.9M |
| May 7, 2025 | $-3.75 | $-0.67 | — | $10.0M |
| Mar 13, 2025 | $-1.80 | $-0.17 | — | $12.5M |
News
Seres Therapeutics (MCRB) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to earnings of $0.94 per share a year ago.
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following tre…
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Pha…
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.48 and traded as low as $2.70. Seres Therapeutics shares last traded at $2.72, with a volume of 60,380 shares changing hands. Analyst Upgrades and Downgrades Several
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $4.73 and traded as low as $3.35. Seres Therapeutics shares last traded at $3.48, with a volume of 71,192 shares trading hands. Analysts Set New Price Targets
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Profitability This table compares Celldex Therapeutics and Seres
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Emp…
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026.